PATIENT CHARACTERISTICS AND THE EFFECTS OF INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH GUILLAIN-BARRE SYNDROME

Abstract

Conclusion - In this study, demyelinating form was more frequent than axonal form. A total of 2 g/kg dose of IVIg treatment administered for 5 days as a standard in GBS patients ensured a significant improvement on both disability and early and late administration and early administration of the treatment does not lead to any difference in intensive care unit and rehabilitation requirements.